On October 3, the Colorado Prescription Drug Affordability Board (PDAB) voted to establish an upper payment limit (UPL) for Enbrel, effective January 1, 2027, making Colorado the first state to implement such a cap. The UPL, set slightly above the Medicare Fair Price at $600 per 50 mg unit, will apply to all purchases and payer reimbursements under state law. Although statute allows the UPL to take effect within six months, the Board delayed implementation until 2027.
Prior to the vote, Aimed Alliance submitted a letter urging caution in the PDAB’s rulemaking process. The letter raised concerns about past data errors, potential unintended consequences such as non-medical switching, and the need for safeguards to protect patients stable on existing treatments. While the Board indicated it could withdraw the UPL if issues arise, Aimed Alliance emphasized that withdrawal alone would not adequately protect patients. Learn more and read the letter here.
Last Updated on October 8, 2025 by Aimed Alliance
